Search TMCI
Treace Medical Concepts, Inc.
NasdaqGS · CIK 1630627
Last close4.39
Daily change+0.06 (1.39%)
10 Years gain-82.80%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TMCI · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
31.9Momentum
63.6Acceleration
77.0Confidence
83.0Annual Revenue7
Quarterly Revenue20
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth10.7 / 25
Quality6.7 / 25
Capital Efficiency1.5 / 20
Balance Sheet9.1 / 15
Shareholder Economics2.2 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 2.7193 percentage points.
ROIC expansionROIC improved by 9.4387 percentage points.
Warnings
Low interest coverage · HIGHInterest coverage is -11.1855x.
Key Metrics
Revenue Growth TTM-1.58%OK
Revenue CAGR 3Y14.46%OK
Gross Margin79.12%OK
Operating Margin-34.06%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-58.76%OK
Incremental Operating Margin 3Y-39.64%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.81%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $212.69M | $169.75M | -$54.15M | -$15.97M | -$29.49M | 79.81% | -25.46% | -13.86% | -46.23% | 63.27M |
| 2025 FY Dec 31, 2024 | $209.36M | $168.26M | -$55.69M | -$37.17M | -$48.76M | 80.37% | -26.6% | -23.29% | -55.59% | 62.11M |
| 2025 FY Dec 31, 2023 | $187.12M | $151.94M | -$51.43M | -$34.58M | -$46.03M | 81.2% | -27.48% | -24.6% | -81.47% | 60.85M |
| 2024 FY Dec 31, 2022 | $141.84M | $116.31M | -$34.84M | -$30.65M | -$45.49M | 82% | -24.57% | -32.07% | -113.3% | 55.28M |
| 2023 FY Dec 31, 2021 | $94.42M | $77.53M | -$16.51M | -$17.19M | -$19.90M | 82.11% | -17.49% | -21.07% | -86.15% | 48.42M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $190.18M | sum latest 4 fiscal quarters Revenue | OK | 0001630627-26-000018, 0001193125-25-269556 |
| Revenue Growth TTM | -1.58% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001630627-26-000018, 0001193125-25-269556 |
| Revenue CAGR 3Y | 14.46% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-079167 |
| Revenue CAGR 5Y | 29.96% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-079167 |
| Gross Profit CAGR 3Y | 13.43% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-079167 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001630627-26-000018, 0001193125-25-269556 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 79.12% | Gross Profit / Revenue | OK | 0001630627-26-000018, 0001193125-25-269556 |
| Operating Margin | -34.06% | Operating Income / Revenue | OK | 0001630627-26-000018, 0001193125-25-269556 |
| ROIC | -58.76% | NOPAT / Average Invested Capital | OK | 0001630627-26-000018, 0001193125-25-269556 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001630627-26-000018 |
| Interest Coverage | -11.19x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 2.9x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.81x | (Cash + Short-term Investments) / Total Debt | OK | 0001630627-26-000018 |